DMD genomic deletions characterize a subset of progressive/higher-grade meningiomas with poor outcome

Clicks: 271
ID: 111739
2018
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #29 of 438 articles by views in acta neuropathologica

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 438 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Progressive meningiomas that have failed surgery and radiation have a poor prognosis and no standard therapy. While meningiomas are more common in females overall, progressive meningiomas are enriched in males. We performed a comprehensive molecular characterization of 169 meningiomas from 53 patients with progressive/high-grade tumors, including matched primary and recurrent samples. Exome sequencing in an initial cohort (n = 24) detected frequent alterations in genes residing on the X chromosome, with somatic intragenic deletions of the dystrophin-encoding and muscular dystrophy-associated DMD gene as the most common alteration (n = 5, 20.8%), along with alterations of other known X-linked cancer-related genes KDM6A (n =2, 8.3%), DDX3X, RBM10 and STAG2 (n = 1, 4.1% each). DMD inactivation (by genomic deletion or loss of protein expression) was ultimately detected in 17/53 progressive meningioma patients (32%). Importantly, patients with tumors harboring DMD inactivation had a shorter overall survival (OS) than their wild-type counterparts [5.1 years (95% CI 1.3–9.0) vs. median not reached (95% CI 2.9–not reached, p = 0.006)]. Given the known poor prognostic association of TERT alterations in these tumors, we also assessed for these events, and found seven patients with TERT promoter mutations and three with TERT rearrangements in this cohort (n = 10, 18.8%), including a recurrent novel RETREG1–TERT rearrangement that was present in two patients. In a multivariate model, DMD inactivation (p = 0.033, HR = 2.6, 95% CI 1.0–6.6) and TERT alterations (p = 0.005, HR = 3.8, 95% CI 1.5–9.9) were mutually independent in predicting unfavorable outcomes. Thus, DMD alterations identify a subset of progressive/high-grade meningiomas with worse outcomes.
Reference Key
juratli2018actadmd Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Tareq A. Juratli;Devin McCabe;Naema Nayyar;Erik A. Williams;Ian M. Silverman;Shilpa S. Tummala;Alexandria L. Fink;Aymen Baig;Maria Martinez-Lage;Martin K. Selig;Ivanna V. Bihun;Ganesh M. Shankar;Tristan Penson;Matthew Lastrapes;Dirk Daubner;Matthias Meinhardt;Silke Hennig;Alexander B. Kaplan;Shingo Fujio;Benjamin M. Kuter;Mia S. Bertalan;Julie J. Miller;Julie M. Batten;Heather A. Ely;Jason Christiansen;Gustavo B. Baretton;Anat O. Stemmer-Rachamimov;Sandro Santagata;Miguel N. Rivera;Fred G. Barker;Gabriele Schackert;Hiroaki Wakimoto;A. John Iafrate;Scott L. Carter;Daniel P. Cahill;Priscilla K. Brastianos;Tareq A. Juratli;Devin McCabe;Naema Nayyar;Erik A. Williams;Ian M. Silverman;Shilpa S. Tummala;Alexandria L. Fink;Aymen Baig;Maria Martinez-Lage;Martin K. Selig;Ivanna V. Bihun;Ganesh M. Shankar;Tristan Penson;Matthew Lastrapes;Dirk Daubner;Matthias Meinhardt;Silke Hennig;Alexander B. Kaplan;Shingo Fujio;Benjamin M. Kuter;Mia S. Bertalan;Julie J. Miller;Julie M. Batten;Heather A. Ely;Jason Christiansen;Gustavo B. Baretton;Anat O. Stemmer-Rachamimov;Sandro Santagata;Miguel N. Rivera;Fred G. Barker;Gabriele Schackert;Hiroaki Wakimoto;A. John Iafrate;Scott L. Carter;Daniel P. Cahill;Priscilla K. Brastianos;
Journal acta neuropathologica
Year 2018
DOI
doi:10.1007/s00401-018-1899-7
URL
https://link.springer.com/article/10.1007/s00401-018-1899-7
Keywords
pathology neurosciences

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.